Literature DB >> 1511188

Cell cycle regulation and the p53 tumor suppressor protein.

W E Mercer1.   

Abstract

Somatic mutations of the p53 gene have been implicated as causal events in the formation of a large number of common human tumors. Several lines of evidence suggest that the nuclear phosphoprotein encoded for by the wild-type gene (wt-p53) plays a role in regulating cell proliferation. Wt-p53 protein encodes a potent negative growth regulatory function that is lacking in mutant forms of the protein found in human tumors. In this review, the relationship between the expression of wt-p53 protein and cell proliferation is examined with emphasis on recent studies that provide clues as to the possible role that p53 plays in cell cycle regulation. A model for the action of p53 in regulating cell proliferation is proposed in which wt-p53 acts as a "checkpoint" protein to control the transit of cells through the restriction point in late G1-phase. After cells pass this "checkpoint" they become committed to enter S-phase and initiate DNA replication. This checkpoint function may be defective in cells that lack p53, express mutant p53, or in which the antiproliferative form of the protein is functionally inactive. Under these conditions stringent control of the initiation of DNA replication may no longer be possible, providing an environment conducive to the emergence oncogenic clones.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511188

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  13 in total

1.  Sequence-specific transcriptional activation is essential for growth suppression by p53.

Authors:  J A Pietenpol; T Tokino; S Thiagalingam; W S el-Deiry; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

Review 2.  Antisense oncogene and tumor suppressor gene therapy of cancer.

Authors:  W W Zhang
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

3.  HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells.

Authors:  Xufeng Chen; Patty Wong; Eric Radany; Jeffrey Y C Wong
Journal:  Cancer Biother Radiopharm       Date:  2009-12       Impact factor: 3.099

4.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

5.  Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts.

Authors:  P Muganda; O Mendoza; J Hernandez; Q Qian
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53.

Authors:  S J Ullrich; K Sakaguchi; S P Lees-Miller; M Fiscella; W E Mercer; C W Anderson; E Appella
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

7.  Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest.

Authors:  D Lin; M Fiscella; P M O'Connor; J Jackman; M Chen; L L Luo; A Sala; S Travali; E Appella; W E Mercer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  The melanoma differentiation associated gene mda-7 suppresses cancer cell growth.

Authors:  H Jiang; Z Z Su; J J Lin; N I Goldstein; C S Young; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

9.  Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal.

Authors:  E Gottlieb; R Haffner; T von Rüden; E F Wagner; M Oren
Journal:  EMBO J       Date:  1994-03-15       Impact factor: 11.598

10.  The Expression and Correlation of iNOS and p53 in Oral Squamous Cell Carcinoma.

Authors:  Lan Yang; Youyuan Wang; Lvhua Guo; Liping Wang; Weiliang Chen; Bin Shi
Journal:  Biomed Res Int       Date:  2015-10-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.